Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 33.9% in January

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 109,000 shares, a decline of 33.9% from the December 31st total of 164,900 shares. Based on an average daily volume of 1,800,000 shares, the short-interest ratio is currently 0.1 days. Approximately 2.7% of the shares of the company are sold short.

Virax Biolabs Group Price Performance

NASDAQ:VRAX remained flat at $1.69 during trading on Friday. The company’s stock had a trading volume of 119,104 shares, compared to its average volume of 351,737. Virax Biolabs Group has a 52-week low of $0.60 and a 52-week high of $9.00. The company has a 50 day simple moving average of $2.03 and a 200 day simple moving average of $2.21.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.